TxCell and Ospedale San Raffaele collaborate on CAR-Treg biology

26 April 2016

French biotech firm TxCell (Euronext Paris: TXCL) has entered into a strategic R&D collaboration with the prestigious Italian research institute Ospedale San Raffaele (OSR). The collaboration will include a development arm focused on lupus nephritis, as well as a research program dedicated to CAR-Treg biology.

The development part of the collaboration will focus on the non-clinical development of chimeric-antigen-receptor engineered regulatory T (CAR-Treg) cells for the treatment of lupus nephritis, one of the most serious complications of lupus, a chronic autoimmune disease affecting over 5 million people worldwide. No financial terms of the accord have been disclosed.

TxCell scientists identified a first relevant antigenic target for its CAR-Treg cellular therapy product. They successfully created a CAR-Treg product candidate by engineering FoxP3+ Treg cells with a CAR. This CAR integrates the binding domain of a pathogenic antibody from patients suffering from lupus nephritis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK